US EditionGeneticure’s test obtains US patent to predict renal denervation response
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
US patent issued for algorithm to predict renal denervation response - Interventional News
Cleveland Clinic Geneticure has announced that the US Patent and Trademark Office has granted a patent for a genetic-based weighted algorithm model for predicting response to renal denervation. This patent protects Geneticure’s proprietary method of using a patient’s genetic profile to predict their likelihood of benefiting from renal denervation—a minimally invasive procedure used to treat hypertension. “Renal denervation has demonstrated the a…
US patent issued for algorithm to predict renal denervation response - Cardiovascular News
Cleveland Clinic Geneticure has announced that the US Patent and Trademark Office has granted a patent for a genetic-based weighted algorithm model for predicting response to renal denervation. This patent protects Geneticure’s proprietary method of using a patient’s genetic profile to predict their likelihood of benefiting from renal denervation—a minimally invasive procedure used to treat hypertension. “Renal denervation has demonstrated the a…
Geneticure’s test obtains US patent to predict renal denervation response
The US Patent and Trademark Office has granted a patent to Geneticure for its genetic test to predict response in renal denervation.The post Geneticure’s test obtains US patent to predict renal denervation response appeared first on Medical Device Network.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
